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Abstract
Background: The use of noninvasive intermittent positive pressure ventilation (NIPPV) in chronic obstructive
pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure remains controversial as long-term
data are almost lacking.
The aim was to compare the outcome of 2-year home-based nocturnal NIPPV in addition to rehabilitation (NIPPV +
PR) with rehabilitation alone (PR) in COPD patients with chronic hypercapnic respiratory failure.
Methods: Sixty-six patients could be analyzed for the two-year home-based follow-up period. Differences in
change between the NIPPV + PR and PR group were assessed by a linear mixed effects model with a random
effect on the intercept, and adjustment for baseline values. The primary outcome was health-related quality of life
(HRQoL); secondary outcomes were mood state, dyspnea, gas exchange, functional status, pulmonary function, and
exacerbation frequency.
Results: Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire
compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the
addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to
-4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea
(Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO2 -0.4 kPa (-0.8 to
-0.2; p = 0.01); PaO2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)),
Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1
second (115 ml (19 to 211; p = 0.019)). Exacerbation frequency was not changed.
Conclusions: The addition of NIPPV to pulmonary rehabilitation for 2 years in severe COPD patients with chronic
hypercapnic respiratory failure improves HRQoL, mood, dyspnea, gas exchange, exercise tolerance and lung
function decline. The benefits increase further with time.
Trial registration: ClinicalTrials.Gov (ID NCT00135538).
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease leading to severe dyspnea at low exer-
cise levels, reduced health-related quality of life
(HRQoL) and high mortality rates [1].
Pulmonary rehabilitation (PR) improves dyspnea, exer-
cise capacity, and HRQoL in patients with COPD [2].
These positive effects can be maintained well if the exer-
cise training is continued at home after initial intensive
PR [3]. However, in severe COPD patients, PR may be
difficult to perform, and effects may be less maintainable
at home [4]. Therefore, there is a need for additive
therapies enhancing the effectiveness of PR, especially in
patients with severe COPD.
We recently showed that the addition of 3-month
nocturnal noninvasive intermittent positive pressure
ventilation (NIPPV) to an intensive multidisciplinary
rehabilitation program improves the outcomes of PR in
severe COPD patients with chronic hypercapnic respira-
tory failure [5]. Three other studies have also investi-
gated noninvasive ventilation in combination with PR,
but assessed short-term effects only [6-8]. A few studies
showed conflicting results of long-term effects of NIPPV
in COPD [9-11]. However, these studies did not add
NIPPV to PR and ventilator settings used were probably
too low to provide beneficial effects [12]. The present
study explores whether the initial positive effects of 3-
month NIPPV in addition to PR, with the use of suffi-
cient ventilator settings, can be maintained over 2-year
home-based follow-up in COPD patients with chronic
hypercapnic respiratory failure. Outcome parameters
were HRQoL, mood state, dyspnea scores, gas exchange,
functional status, pulmonary function, and exacerbation
frequency.
Methods
Patients
Patients with COPD GOLD stage III or IV [1] (forced
expiratory volume in 1 second (FEV1)/forced vital capa-
city < 70% and FEV1 < 50% predicted), aged between 40
and 76 years, in stable clinical condition (no exacerba-
tion in the four weeks prior to study participation
together with a pH>7.35); and with chronic hypercapnic
respiratory failure (an arterial carbon dioxide pressure
(PaCO2) > 6.0 kPa at rest while breathing room air)
were included. Exclusion criteria were: cardiac or neuro-
muscular diseases limiting exercise tolerance; previous
exposure to a pulmonary rehabilitation program during
the previous 18 months or previous exposure to chronic
NIPPV ever; or an apnea/hypopnea index ≥ 10/hour. An
overnight polygraphy (Embletta pds, Medcare Automa-
tion BV, Amsterdam, the Netherlands) was performed
in all patients with a body mass index ≥ 30 kg/m
2,a n d
in patients who snored or had complaints of disrupted
sleep, excessive daytime sleepiness, or morning head-
ache. The study was approved by the local Medical
Ethics Committee of the University Medical Centre
Groningen, University of Groningen and was registered
at ClinicalTrials.Gov (ID NCT00135538). All partici-
pants gave written informed consent to participate.
Study design
Randomization
The study design was randomized controlled with paral-
lel-groups. Patients were assigned to nocturnal NIPPV
in addition to rehabilitation (NIPPV + PR) or to rehabi-
litation alone (PR). Randomization was computerized
and performed by an independent statistician, with
minimization for FEV1 (≤ 1.2 L or > 1.2 L), PaCO2 (≤
7.0 kPa or > 7.0 kPa), and body mass index (≤ 30 kg/m
2
or > 30 kg/m
2) [13].
Rehabilitation
After a 12-week multidisciplinary in-hospital rehabilita-
tion program [5], all patients continued with a home-
based rehabilitation program, with or without nocturnal
NIPPV. In the current manuscript results of the home-
based period are presented; results of the multidisciplin-
ary in-hospital program have been reported separately
[5]. The home-based program consisted of physiother-
apy at a community practice 1-2 times a week during
the whole study period, with or without home NIPPV.
Most patients visited the physiotherapist two times a
week. A few patients (both from the NIPPV + PR group
a n dt h eP Rg r o u p )v i s i t e dt he physiotherapist once a
week because the distance to travel to the physiotherapy
practice was too long. All participating physiotherapists
in the study were members of the Northern COPD phy-
siotherapists group, which means that the physiothera-
pists were regularly taught in COPD exercise programs,
a n dw o r ki naw e l l - e q u i p p e de n v i r o n m e n tf o rC O P D
patients.
Each session consisted of 30-minute periods of cycling
exercises, walking, and inspiratory muscle training each.
The cycling protocol consisted of intervals of one min-
ute loaded cycling (aimed at 140% of a patient’si n i t i a l
peak work rate on cycle ergometry), and one minute
unloaded cycling, during 30 minutes [14]. Inspiratory
muscle training was performed on an inspiratory thresh-
old device at an interval basis (two minutes of loaded
breathing, followed by one minute rest), starting with
the threshold resistance on 30% of baseline maximal
inspiratory pressure (PImax), increasing the resistance
with 5-10% per session until 70% PImax was reached
[15]. In patients with low fat free mass, strength training
was added. Patients were also instructed to stay as active
as possible at home, they were stimulated to walk at
least each day and to train with their inspiratory device.
All sessions were noted in a diary in order to monitor
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more, there was regular contact with the physiothera-
pists participating in this study. If patients did not show
up without a good reason for a longer period they were
regarded as drop-outs (3 patients in the PR group and 1
patient in the NIPPV + PR group). Oxygen was used
during training to maintain arterial oxygen saturation
>90%.
NIPPV
In the NIPPV + PR group, patients were instituted on
nocturnal bilevel NIPPV. Noninvasive ventilation was
supplied through a pressure cycled ventilator, applying
both inspiratory and expiratory pressure (BiPAP; Syn-
chrony, Respironics, INC., Murrysville, PA, USA). A
nasal or full face mask (Mirage mask, ResMed Ltd, UK)
of the proper size was used. The ventilator was set in a
spontaneous/timed mode (S/T), with a backup fre-
quency. Inspiratory positive airway pressure (IPAP) was
increased up to maximal tolerated pressure and titrated
towards an optimal correction of nocturnal arterial
blood gases (PaCO2<6.0 kPa and arterial oxygen pres-
sure (PaO2) >8.0 kPa). Effectiveness of NIPPV was initi-
ally monitored by means of arterial blood gas
measurements during the night [5], during the home
based period NIPPV effectiveness was monitored by
means of transcutaneous O2-saturation and PCO2tc
measurements performed with the TOSCA
® (Type
TOSCA
® 500, Linde Medical Sensors AG, Basel, Swit-
zerland) [16,17]. Ventilator compliance was determined
from the ventilator counter readings. A specialized
nurse from our department of home mechanical ventila-
tion supervised the home mechanical ventilation.
Outcomes
Outcome measures of the home-based period were per-
formed just before the start of this period (after 3 months
in-hospital rehabilitation), and then after 6, 12, 18, and
after 24 months (Figure 1). The primary outcome was
predefined to be HRQoL, assessed by the Chronic
Respiratory Questionnaire (CRQ) [18]. Additionally,
HRQoL was measured with the Maugeri Respiratory Fail-
ure questionnaire (MRF-28) [19], and Severe Respiratory
Insufficiency questionnaire (SRI) [20]. Secondary out-
comes were mood state (Hospital Anxiety and Depres-
sion scale (HADS) [21]), dyspnea scores (Medical
Research Council (MRC) [22]), gas exchange (arterial
blood gases), functional status (6-minute walking dis-
tance (6MWD), activity level (Groningen Activity and
Restriction Scale (GARS) [23])), pulmonary function
(FEV1, vital capacity, and lung volumes), and exacerba-
tion frequency. An exacerbation was defined as an epi-
sode of increased pulmonary complaints for which (an
increase in) oral steroids and/or antibiotics was needed
(Figure 1). Details are given in the additional file 1.
Sample size
To detect a clinically relevant change in the CRQ score
of 10 points with 80% power, 40 patients per group
were needed [24]. The target sample size was 50
patients per group, considering a probability of 20%
drop-out of randomized patients.
Analyses and Statistics
Continuous variables were summarized with the use of
means and standard deviations or medians with inter-
quartile ranges depending on their distribution. Treat-
ment effects or differences in change between the PR
and NIPPV + PR group, with the associated 95% CI and
p-value, were assessed by a linear mixed effects model
with a random effect on the intercept, with adjustment
for the values at the start of the period [25]. Outcomes
were screened for linearity by visual inspection of all
plots. A full data set analysis was performed, signifying
intention-to-treat, with all data of all patients available
at the start of the home-based period included for ana-
lyses and all available data used for analyses until
patients dropped out. A p < 0.05 was considered statisti-
cally significant. Analyses were performed by an inde-
pendent statistician (JV) with SPSS 16.0.
Results
Patients
Thirty-two patients in the PR group and 24 patients in
the NIPPV + PR group completed the 3-month multi-
disciplinary program [5], and were included in the pre-
sent report (Figure 1, Table 1).
24 months
Allocated to NIPPV + rehabilitation
(n= 37)
Before
n = 15
Drop-outs (n=3)
Allocated to rehabilitation 
(n=35)
Randomized
(n =72)
Early drop-outs (n=6)
- 2 withdrew
- 2 died
- 2 diagnosed with cancer
Drop-outs (n=7)
Run in
QoL; ABG; 6MWD; LF
Measurements
QoL; ABG; 6MWD; LF N=20
3-months QoL; ABG; 6MWD; LF n = 24 N=32
6-months QoL; ABG; 6MWD; LF N=23 N=29
12-months QoL; ABG; 6MWD; LF N=27 N=18
18-months QoL N=22 N=17
Drop-outs (n=1)
Drop-outs (n=5)
Drop-outs (n=1)
Drop-outs (n=2) 
Drop-outs (n=3)
Drop-outs (n=2)
Drop-outs (n=5)
Drop-outs (n=2)
N=35 N=31
Figure 1 Flow diagram of the study progress. The present article
presents the results of the home-based 3-24 month period, shown
with a black square around it. QoL: health-related Quality of Life;
ABG: arterial blood gases; 6MWD: 6-minute walking distance; LF:
lung function measurements.
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ities, the most common being osteoporosis (NIPPV +
PR group: 3 patients (13%); PR group: 4 patients (13%));
hypertension (NIPPV + PR group: 7 patients (29%); PR
group: 8 patients (25%)); cardiac dysfunction and/or
chronic atrial fibrillation (NIPPV + PR group: 8 patients
(33%); PR group: 5 patients (16%)); depression (NIPPV
+ PR group: 4 patients (17%); PR group: 8 patients
(25%)); and diabetes mellitus (PR group: 8 patients
(25%)).
Diuretics were used by 6 patients in the NIPPV + PR
group and 11 patients in the PR group at the start of
the study period (not significantly different), but were
started in significantly more patients in the PR group
(NIPPV + PR group: 3 patients; PR group: 10 patients; p
=0 . 0 3 ) ,s ot h a ta tt h ee n do ft h es t u d yp e r i o ds i g n i f i -
cantly more patients in the PR group used diuretics
compared to the NIPPV + PR group (p = 0.003).
At the start of the study period, 51 patients (91%)
used inhaled corticosteroids, and 55 patients (98%) used
bronchodilators (inhaled beta-agonist or anticholinergic
medication) (Table 1). During the study period no
further changes were made, except for the one patient
in the PR group who initially did not want to use a
bronchodilator but started on tiotropium during the fol-
low up. At the start of the study period, 24 patients
(43%) used oral corticosteroids (all at a standard dosage
of 5 mg 3 times a week to 10 mg/day prescribed by
their own pulmonologist to prevent exacerbations).
Changes in oral steroid use were made in 6 patients: in
2 PR group patients oral steroids were started, in 3 PR
group patients the dosage was increased, and in 1 PR
patient oral steroids could be stopped. Thirteen patients
(23%) were on theophylline, in one patient in the PR
group theophylline was started during the study period.
At the start of the study period 2 patients were on pro-
phylactic antibiotics, during the study period azithromy-
cin or doxycycline was started in an additional 3
patients in the NIPPV + PR group and 7 patients in the
PR group (not significantly different).
Treatment compliance and drop-outs for the complete
study period
During the home-based follow-up period, nine patients
in the NIPPV + PR group did not complete the study
(three patients withdrew from follow-up, one patient
h a da na o r t ad i s s e c t i o n ,a n df i v ep a t i e n t s( 2 1 % )d i e d ;
two from a COPD exacerbation, two suddenly at home
without further cause verification, and one patient with-
out further information). In the NIPPV + PR group,
drop-outs had a significantly lower baseline PaO2 com-
pared to completers (PaO2 7.2 (0.8) kPa vs. 8.2 (1.0)
kPa; p = 0.02).
During the home-based period, 12 patients in the PR
group did not complete the study (three patients were
non-compliant, one received a lung transplantation, one
got an ischemic stroke, one patient’s clinical condition
deteriorated making further measurements impossible,
one was treated with CPAP by his own pulmonologist,
and five patients (16%) died, all from a COPD exacerba-
tion). In the PR group, at baseline, drop-outs had a sig-
nificantly higher RV/%TLC ratio (63 (7) vs. 57 (8); p =
0.04), a worse 6MWD (232 (98) m vs. 347 (99) m; p =
0.004), and worse HRQoL (CRQ total, 69 (11) vs. 86
(20) points; p = 0.005) than those who completed the
study.
There were no significant differences between the
groups at the start of the study period (Table 1, addi-
tional file 1, Table S1 and Table S2), except for slightly
better HRQoL scores in the NIPPV + PR group com-
pared to the PR group (CRQ total score 96.8 (15.3) vs.
87.1 (18.9) points; p = 0.044; CRQ fatigue score 18.8
(3.9) vs. 15.4 (5.6) points, p = 0.015; SRI attendant
symptoms: 71.1 (19.6) vs. 60.2 (19.6)%, p = 0.032. When
the analysis was repeated with only patients who com-
pleted the whole study, there were no baseline differ-
ences. The number of patients that died during the
study was the same in both groups (five patients).
NIPPV settings
The mean IPAP at the start of the home-based follow-
up period was 23 (4) cm H2O, with a mean EPAP of 6
(2) cm H2O, mean respiratory rate on NIPPV of 18 (3)
breaths/min, an inspiration time of 1.0 (0.1) seconds,
and a rise time of 1.2 (0.6) seconds. Fourteen patients
used oxygen during the day (median flow rate of 2 L/
m i n( r a n g e0 . 7 5t o4 ) ) ,t h e ya l s ou s e do x y g e nw h i l eo n
Table 1 Characteristics of the patients included at the
start of the follow-up period
Characteristics NIPPV + rehabilitation Rehabilitation
Subjects - n 24 32
Gender - M:F 16: 8 17: 15
Age - yrs, mean (SD) 63 (10) 61 (8)
Patients on LTOT - n (%) 14 (58%) 18 (56%)
BMI - kg/m
2, mean (SD) 27.2 (5.1 27.0 (5.8
Active smokers, n (%) 5 (21%) 11 (34%)
Pack years - yrs, median (IQR) 42 (31-57) 43 (24-58)
Medication, n (%)
inhaled corticosteroids 22 (92%) 29 (91%)
oral corticosteroids 10 (42%) 14 (44%)
bronch odilators 24 (100%) 31 (97%)
theophylline 5 (21%) 8 (25%)
Data are means (SD) or median (interquartile range, IQR), unless otherwise
indicated. LTOT: long-term oxygen therapy; BMI: body mass index. Health-
related quality of life scores, blood gases, exercise tolerance, and lung
function data are presented in Figures 2-5 and additional file 1 tables 1-6.
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to 4 L/min)). Only minor adjustments were made during
the study period in order to improve (daytime) arterial
blood gases more. In 6 patients IPAP was increased by a
median of 4 cm H2O( r a n g e2t o5c mH 2O), in three
patients IPAP was decreased by a median of 2 cm H2O
(range 1 to 3 cm H2O) to optimize comfort). Daytime of
the nocturnal transcutaneous measurements (TOSCA
®)
are presented in additional file 1, Table S3. After two
years, mean IPAP in the 15 remaining patients was 23
(4) cm H2O, mean EPAP 6 (2) cm H2O, mean respira-
tory rate on NIPPV 18 (3) breaths/min, inspiration time
0.9 (0.2) seconds, and rise time 1.2 (0.6) seconds. Seven
patients used oxygen during the day (median flow rate
of 1.5 L/min (range 1 to 3)), however only four of them
needed oxygen when on the ventilator (median flow rate
of 2 L/min (range 2 to 4 L/min)).
One patient was ventilated through a nose mask, the
remaining through a full face mask. Compliance was
good, after two years patients used their ventilator 94% of
the days (range 75 to 100%), with a median use per day
of 6.9 hours (range 40 minutes to 11.4 hours/24 hours).
Health-related quality of life, mood state, and dyspnea
The change in CRQ total and domain scores did not
differ between both groups (Table 2, for absolute num-
bers see additional file 1, Table S1). The MRF-28 total
score, and its domains daily activities and invalidity,
improved more in the NIPPV + PR group than the PR
group (difference in change for MRF-28 total score:
-13.4% (95% CI -22.7 to -4.2; p = 0.005), Figure 2, addi-
tional file 1, Table S4). The SRI physical functioning
domain improved more in the NIPPV + PR group than
the PR group (difference 10.7% (95% CI 3.8 to 17.6; p =
0.003)), additional file 1, Table S2). The HADS and
MRC scores improved more in the NIPPV + PR group
than the PR group (Table 3, for absolute numbers see
additional file 1, Table S5).
Daytime arterial blood gases
Arterial blood gases improved more in the NIPPV + PR
group than the PR group (PaO2 0.8 kPa (95% CI 0.0 to
1.5; p = 0.032); PaCO2 -0.4 kPa (95% CI -0.8 to -0.2; p
= 0.011); HCO3
- - 2.7 mmol/L (95% CI -4.4 to -1.1; p =
0.002); Figure 3, additional file 1, Table S6).
Functional status
The 6MWD was maintained in the NIPPV + PR group,
while it deteriorated in the PR group, the difference in
change being significant (77.3 m (95% CI 46.4 to 108.0;
p < 0.001; Figure 4, additional file 1, Table S6).
The GARS scores improved more in the NIPPV + PR
group than the PR group (Table 3, for absolute numbers
see additional file 1, Table S5).
Pulmonary function
In the NIPPV + PR group, mean FEV1 stabilized or even
slightly increased from 0.89 to 0.95 over time, which was
significantly different from the mean reduction in FEV1
from 0.81 to 0.69 L in the PR group, the difference
between the groups being 115 ml (95% CI 19 to 211; p =
0.019; Figure 5, Table 4, for absolute numbers see addi-
tional file 1, Table S7). There was no difference in VC or
RV/%TLC, although the latter was measured only until
the 12-month time point. There was no difference in
change in maximal inspiratory muscle pressure (PImax)
between the groups (Table 4, additional file 1, Table S7).
Exacerbation frequency
The median exacerbation frequency was 3.0 exacerba-
tions/year in both groups, the median hospitalization
Table 2 Changes in Chronic Respiratory Questionnaire
Change up to 24
months
CRQ total - points
N+R - mean (95% CI) -3.6 (-10.1 to 2.9)
R - mean (95% CI) -2.3 (-7.8 to 3.2)
Adjusted difference in change - mean
(95% CI)*
-1.3 (-9.7 to 7.4)
CRQ dyspnea - points
N+R - mean (95% CI) -1.5 (-4.0 to 0.8)
R - mean (95% CI) 0.0 (-2.1 to 2.1)
Adjusted difference in change - mean
(95% CI)*
-1.7 (-4.8 to 1.5)
CRQ fatigue - points
N+R - mean (95% CI) -1.5 (-3.6 to 0.4)
R - mean (95% CI) -1.5 (-2.9 to 0.2)
Adjusted difference in change - mean
(95% CI)*
-0.2 (-2.7 to 2.3)
CRQ emotion - points
N+R - mean (95% CI) -1.1 (-3.6 to 1.3)
R - mean (95% CI) -0.4 (-2.5 to 1.7)
Adjusted difference in change - mean
(95% CI)*
-0.8 (-4.0 to 2.5)
CRQ mastery
N+R - mean (95% CI) -0.8 (-2.5 to 0.6)
R - mean (95% CI) -0.7 (-2.1 to 0.4)
Adjusted difference in change - mean
(95% CI)*
0.0 (-2.1 to 2.1)
Data presented are mean changes (95% confidence intervals). * The
differences in change are the treatment effects or between groups differences
in change (95% CI), with adjustment for the baseline values. A positive
difference in change signifies more improvement over time with NIPPV + PR
relative to PR alone.
The CRQ (chronic respiratory questionnaire) contains a total score (score range
from best (140) to worst (20)), and 4 different domains: dyspnea domain
(score range from best (35) to worst (5)), fatigue domain (score range from
best (28) to worst (4)), emotion domain (score range from best (49) to worst
(7)), mastery domain score range from best (35) to worst (5)). N+R: NIPPV +
rehabilitation group; R: rehabilitation group.
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not significantly different over time or between groups.
Also, the median number of hospitalization days/year
was also not significantly different over time or between
groups.
Discussion
Our study shows for the first time that home-based
NIPPV + PR provides long-term benefit as to HRQoL,
mood state, dyspnea, gas exchange, exercise tolerance,
and FEV1 over PR alone in patients with severe COPD
with chronic hypercapnic respiratory failure.
We believe the present RCT to be unique being the
first to show that the addition of NIPPV improves FEV1
over 2-year follow-up compared to rehabilitation alone.
The rehabilitation group had an average decline in post-
bronchodilator FEV1 of 83 ml/yr, while in the NIPPV +
PR group this was 17 ml/yr. Except for smoking cessa-
tion [26] and, in some studies, the use of inhaled corti-
costeroids [27], no interventions have been shown to
slow down FEV1 decline in COPD. Notably, effects
found with smoking cessation and inhaled corticoster-
oids were smaller compared to the difference found in
our study of 66 ml/year, which is a large effect in these
severe COPD patients. We speculate that NIPPV stabi-
lizes FEV1 either by volume expansion and/or a decrease
in airflow obstruction. We were unable to show volume
expansion, as we did not show significant changes in
vital capacity, lung volumes or hyperinflation. However,
lung volumes were measured until 12 months, so that
volume expansion could still have occurred during the
last year. Independently from changes in lung volumes,
FEV1 stabilization is probably caused by a decrease in
airflow obstruction. We speculate that a reduction in
hypercapnia achieved with NIPPV reduces salt and
water retention thereby reducing air wall edema [28].
Although speculative, reduced air wall edema might also
exhibit a positive effect on airway wall remodeling by
reducing inflammation when muscle fibers become less
overstretched. An increase of FEV1 at short-term has
been previously reported in studies using high inflation
pressures with significant reductions in hypercapnia
Figure 2 Maugeri Respiratory Failure scores.M R Fs c o r e sa tt h ed i f f e r e n tm e a s u r e m e n tp o i nts in the NIPPV + rehabilitation group (black
triangles) and the rehabilitation group (grey blocks). Lower scores signify better quality of life. The change was significantly better in the NIPPV
+ rehabilitation group (p < 0.02).
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tance to improve of lung function [12].
This is the first randomized clinical trial to demon-
strate that NIPPV is effective in improving daytime
arterial blood gases at the longer term. This requires
that effective ventilation during the night was achieved.
Although it is obvious that effective ventilation is the
first condition that should be met with NIPPV, it
appears that in most NIPPV studies rather low positive
pressure were used, so that outcomes have often been
difficult to interpret [6,8-11]. We believe that close
monitoring during the night is essential in improving
gas exchange and that higher pressures are important to
achieve good compliance [29] and effective ventilation
[12,29-31]. High compliance as we achieved is essential.
This all will have contributed to the positive clinical
effects we found.
Exercise tolerance remained stable in the NIPPV + PR
group, while it deteriorated in the PR group. A gradual loss
of exercise tolerance at long term has been shown before
in moderate to severe COPD patients, despite a out-of-
hospital maintenance rehabilitation program [3,32-34].
Probably, positive effects of NIPPV on arterial blood gases
give patients a more favorable condition to train and thus
prevent deterioration in their physical condition, thus
stressing the importance of additional therapies in COPD
patients with chronic respiratory failure at long term.
Table 3 Changes in Groningen Activity and Restriction
Scale (GARS), Hospital Anxiety and Depression scale
(HADS), and Medical Research Council (MRC)
Change up to 24
months
GARS, total - points
N+R - mean (95% CI) 0.6 (-1.9 to 3.4)
R - mean (95% CI) 4.6 (2.3 to 6.9)
†
Adjusted difference in change - mean
(95% CI)*
-3.8 (-7.4 to -0.4)‡
HADS, total - points
N+R - mean (95% CI) -0.2 (-3.4 to 2.7)
R - mean (95% CI) 3.6 (1.3 to 5.9)
†
Adjusted difference in change - mean
(95% CI)*
-4.0 (-7.8 to 0.0)‡
MRC - points
N+R - mean (95% CI) 0.2 (-0.2 to 0.4)
R - mean (95% CI) 0.6 (0.4 to 0.8)
†
Adjusted difference in change - mean;
95% CI*
-0.4 (-0.8 to -0.0)‡
Data presented are mean changes (95% confidence intervals). * The
differences in change are the treatment effects or between groups differences
in change (95% CI), with adjustment for the baseline values. A negative
outcome indicates benefit for the NIPPV + rehabilitation group compared to
the rehabilitation group.
GARS: Groningen Activity and Restriction Scale (score range from best (18) to
worst (72)); HADS: Hospital Anxiety and Depression scale (score range from
best (0) to worst (42)); MRC: Medical Research Council dyspnea scale (score
range best (1) to worst (5)); N+R: NIPPV + rehabilitation group; R:
rehabilitation group.
†: p < 0.05, significant difference in change over time within a group or ‡ p<
0.05: significant difference in change between groups.
Figure 3 Daytime arterial blood gases. Daytime arterial blood gases without additional oxygen at the different measurement points in the
NIPPV + rehabilitation group (black triangles) and the rehabilitation group (grey blocks). The change was significantly better in the NIPPV +
rehabilitation group (p < 0.02).
Figure 4 6-minute walking distance.6 M W Di nm e t e r sa tt h e
different measurement points in the NIPPV + rehabilitation group
(black triangles) and the rehabilitation group (grey blocks). The
change was significantly better in the NIPPV + rehabilitation group
(p < 0.001).
Duiverman et al. Respiratory Research 2011, 12:112
http://respiratory-research.com/content/12/1/112
Page 7 of 10Although these outcomes are promising, we have to
notify that the results of our primary outcome, HRQoL,
showed uncertain results, with the primary endpoint,
CRQ, not showing any improvement. However, in hind-
sight, we have debated whether the CRQ is the optimal
instrument to assess HRQoL in patients with chronic
respiratory failure. By contrast, the MRF-28 and SRI
were especially developed for patients with chronic
respiratory failure improved, and are therefore probably
more responsive in these patients [12,35]. Furthermore,
we showed improvements in dyspnea scores and depres-
sion scores, both being an important determinant of
HRQoL.
Chronic long-term NIPPV is a costly intervention. In a
next study it would be interesting to add a true costs-
benefit-analysis, as this may play a role in the further
implication of NIPPV in chronic COPD patients. We did
not find a difference between groups in overall exacerba-
tion frequency, hospitalization rate for a COPD exacerba-
tion or the number of hospitalization days. However in
our cohort exacerbations did not occur frequently and
the majority of the exacerbations occurred in a minority
of the patients, so that large inter-individual differences
occurred and data were not normally distributed.
The present study has some limitations. We did not
use sham-ventilation in our control group, hence
patients and investigators were not blinded. Sham-venti-
lation is difficult to implement at home during the long
study period. Secondly, only 72 patients were included
while according to the power calculation 40 patients per
g r o u pw e r en e e d e dt of i n da1 0 - p o i n tc h a n g ei nC R Q
total score. Due to the difficult recruitment and financial
constraints we were unable to further extend the inclu-
sion period. This may have influenced our results due to
a type-II error for false negative outcomes, such as
might have occurred with the CRQ. This does not, how-
ever, affect the observed significant improvements in
our study. Finally, our study was not powered to find a
difference in survival. While survival benefit of noninva-
sive ventilation has been shown one controlled study
[11], clear evidence of improved survival is still lacking
and should be investigated in larger studies.
Conclusions
In conclusion, the present study is the first RCT to
show that, with long-term, 2-year NIPPV in addition to
PR as compared to PR alone, positive effects can be
maintained in HRQoL and gas exchange, while addi-
tional effects can be achieved in functional status (exer-
cise tolerance), mood state, dyspnea scores, and FEV1 in
severe COPD patients with chronic hypercapnic respira-
tory failure. Although larger long-term studies have to
confirm our results and give additional evidence on sur-
vival benefit and cost-effectiveness, with the present
Figure 5 Forced expiratory volume in 1 second (FEV1). FEV1 in
liters (L) at the different measurement points in the NIPPV +
rehabilitation group (black triangles) and the rehabilitation group
(grey blocks). The change was significantly better in the NIPPV +
rehabilitation group (p < 0.02).
Table 4 Changes in Pulmonary function
Change up to 24
months
FEV1 - liters
N+R - mean (95% CI) -0.03 (-0.10 to 0.05)
R - mean (95% CI) -0.14 (-0.20 to -0.08)
†
Adjusted difference in change - mean
(95% CI)*
0.12 (0.02 to 0.21) ‡
VC - liters
N+R - mean (95% CI) -0.01 (-0.19 to 0.17)
R - mean (95% CI) -0.20 (-0.35 to -0.04)
†
Adjusted difference in change - mean
(95% CI)*
0.19 (-0.05 to 0.42)
RV/%TLC
N+R - mean (95% CI) 0.8 (-5.3 to 7.1)
R - mean (95% CI) 0.8 (-4.4 to 6.1)
Adjusted difference in change - mean
(95% CI)*
0.2 (-8.0 to 8.4)
PImax - kPa
N+R - mean (95% CI) 1.1 (0.4 to 2.5)
R - mean (95% CI) -0.6 (-1.9 to 0.6)
Adjusted difference in change - mean
(95% CI)*
1.7 (-0.0 to 3.6)
Data presented are mean changes (95% confidence intervals). * The
differences in change are the treatment effects or between groups differences
in change (95% CI), with adjustment for the baseline values. Lung volumes
and PImax were measured until 12 months only.
FEV1: forced expiratory volume in 1 second in L; VC: maximal vital capacity, L;
RV%TLC: residual volume as a percentage of total lung capacity; PImax:
maximal inspiratory pressure in kPa. N+R: NIPPV + rehabilitation group; R:
rehabilitation group.
†: p < 0.05, significant difference in change over time within a group or ‡ p<
0.05: significant difference in change between groups.
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as an additional intervention next to pulmonary rehabili-
tation in severe COPD patients with chronic hypercap-
nic respiratory failure. Close monitoring of ventilatory
support and the use of sufficiently high inspiratory pres-
sures are probably crucial in obtaining these positive
effects. This study shows that interventions that need a
long period to reach their maximal effect like NIPPV
should be studied over a long time scale, especially in
slowly progressive diseases like COPD. Beneficial effects
may require much time to develop fully and can there-
fore easily be underestimated.
Additional material
Additional file 1: Entitled “Two-year home-based nocturnal
noninvasive ventilation added to rehabilitation in chronic
obstructive pulmonary disease patients: a randomized controlled
trial: measurement information and supplemental tables”, contains
additional information about the measurements used, and additional
information about the results, including absolute changes per group and
results of the nocturnal transcutaneous CO2 and SaO2 measurements
(TOSCA
®®).
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